Bone marrow failure is a condition where the spongy tissue inside your bones stops producing enough healthy blood cells. Since bone marrow is responsible for making red blood cells, white blood cells, and platelets, failure in this system leads to dangerous shortages of one, two, or all three cell types. The result is a cascade of problems: severe anemia, uncontrolled bleeding, and vulnerability to infections that a healthy immune system would easily handle.
How Blood Cell Production Breaks Down
Your bone marrow contains stem cells that continuously divide and mature into the three major blood cell types your body needs. In bone marrow failure, these stem cells either become damaged, stop dividing, or get destroyed before they can do their job. The specific mechanism depends on the cause, but the end result is the same: the marrow becomes “hypocellular,” meaning it’s increasingly filled with fat cells instead of the blood-forming cells that should be there.
One key biological process involves the protective caps on the ends of chromosomes, called telomeres. When telomeres shorten or malfunction, it triggers an immune signaling pathway that pushes cells into a state of permanent shutdown. These senescent cells can no longer divide, and the marrow’s ability to replenish blood cells declines. Aging and chronic low-grade inflammation accelerate this process, which is why bone marrow failure increases the risk of blood cancers in older adults and in patients with inherited marrow disorders regardless of age.
Inherited vs. Acquired Forms
Bone marrow failure falls into two broad categories, and distinguishing between them is critical because treatment differs significantly.
Inherited Bone Marrow Failure Syndromes
These are genetic conditions present from birth, though symptoms sometimes don’t appear until adolescence or adulthood. The most common include:
- Fanconi anemia: A DNA repair disorder, usually inherited from both parents, that causes progressive marrow failure and a high risk of leukemia and solid tumors. Children with Fanconi anemia often have visible birth defects: absent or malformed thumbs, short stature, kidney abnormalities, small head size, and distinctive skin pigmentation changes like café-au-lait spots.
- Dyskeratosis congenita: A disorder of telomere biology, classically identified by three features: abnormal fingernails or toenails, lacy pigmentation patterns on the skin, and white patches inside the mouth. It can also affect the lungs, liver, and bones.
- Diamond-Blackfan anemia: Primarily affects red blood cell production, often diagnosed in the first year of life.
- Shwachman-Diamond syndrome: Affects both marrow function and the pancreas, causing problems with blood cell production and digestion.
Newer genetic syndromes, including GATA2 deficiency and SAMD9/SAMD9L disorders, are being identified more frequently as genetic testing becomes more advanced. Each of these inherited conditions involves a different broken cellular mechanism: faulty DNA repair in Fanconi anemia, shortened telomeres in dyskeratosis congenita, and problems with the cellular machinery that builds proteins in Shwachman-Diamond syndrome and Diamond-Blackfan anemia.
Acquired Bone Marrow Failure
Acquired forms develop later in life in people who were born with normal marrow function. The most well-known is aplastic anemia, where the immune system mistakenly attacks and destroys the marrow’s stem cells. Other acquired causes include exposure to certain chemicals and environmental toxins, viral infections, and certain medications. In many cases, the exact trigger is never identified.
Myelodysplastic syndromes (MDS) are another form of acquired marrow failure. In MDS, the marrow produces blood cells that are abnormal and don’t function properly. These conditions are classified based on the percentage of immature “blast” cells found in the marrow and blood, ranging from low-blast forms (under 5% in the marrow) to higher-blast forms (10 to 19%) that sit closer to the boundary with leukemia. MDS is most common in older adults and carries its own risk of progressing to acute leukemia.
Symptoms and Warning Signs
The symptoms of bone marrow failure directly reflect which blood cell types are running low, and they often develop gradually enough that people don’t recognize them right away.
Low red blood cells cause fatigue, weakness, pale skin, and in severe cases, shortness of breath or signs of heart strain as the heart works harder to deliver oxygen with fewer red cells available. Low platelets lead to easy bruising, tiny red or purple dots on the skin called petechiae, bleeding gums, and frequent nosebleeds. Low white blood cells make you susceptible to infections that can escalate quickly, from skin infections and pneumonia to sepsis.
In inherited forms like Fanconi anemia, physical features may be the first clue. A child with absent thumbs, unusually short stature, or characteristic skin spots may be evaluated for marrow failure before blood counts even drop. Other inherited syndromes have subtler physical signs that require a trained eye to spot.
How Bone Marrow Failure Is Diagnosed
Diagnosis starts with blood tests that reveal low counts in one or more cell lines, but a bone marrow biopsy is the definitive step. This involves taking a small core of bone (usually from the back of the hip) along with a liquid sample of marrow cells. A pathologist examines both samples under a microscope to assess how much of the marrow space is occupied by blood-forming cells versus fat.
The liquid sample (aspirate) is particularly useful for identifying nutritional anemias and leukemias, while the solid core (biopsy) is better at diagnosing aplastic anemia and other conditions where the overall structure of the marrow matters. In many cases, both are needed together to get the full picture. Genetic testing has become increasingly important for confirming inherited syndromes, especially since some don’t cause obvious physical abnormalities.
Treatment and Outlook
Treatment depends entirely on whether the marrow failure is inherited or acquired, and how severe it is.
For acquired aplastic anemia, a stem cell transplant from a matched sibling donor is the preferred option when available. When it isn’t, the standard approach is immunosuppressive therapy designed to stop the immune system from attacking the marrow. This combination therapy produces a response in 60 to 70% of patients with severe aplastic anemia. In a large study of children, 10-year overall survival reached 92% with the most effective regimen, and 84% with an alternative version. Some patients achieve a complete response where blood counts return to normal, while others see a partial improvement that still meaningfully reduces their need for transfusions and their infection risk.
For inherited syndromes, stem cell transplant is often the only path to restoring normal marrow function. However, the specific genetic defect influences how well a patient tolerates the transplant conditioning process. Patients with Fanconi anemia, for instance, are unusually sensitive to certain preparatory treatments because of their underlying DNA repair defect, so transplant protocols have to be modified.
Supportive care plays a major role regardless of the cause. This includes regular blood and platelet transfusions to manage dangerous shortages, antibiotics or antifungal medications to prevent or treat infections, and close monitoring for signs of progression to leukemia or other blood cancers. For some inherited syndromes, growth factors that stimulate blood cell production can help maintain counts without a transplant, at least temporarily.
Long-Term Risks
Bone marrow failure is not a static condition. Both inherited and acquired forms carry an elevated risk of developing blood cancers over time. Chronic low-grade inflammation in the marrow, combined with the ongoing stress on the remaining stem cells, creates an environment where genetic mutations are more likely to accumulate. Patients with Fanconi anemia face a particularly high risk of both leukemia and solid tumors, especially squamous cell cancers of the head, neck, and genital areas. Regular screening for cancer is a standard part of long-term follow-up for anyone living with a bone marrow failure syndrome.